MedTrace Logo

Current Value of Axillary Ultrasound in the Staging of Breast Cancer. Is BSGC Still Necessary?

NCT03193008 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2017-06-20

No results posted yet for this study

Summary

AUS/FNAC allows the identification of tumors without axillary tumor involvement, or with low axillary tumor burden, many of which do not benefit from SLNB, in the staging of early breast cancer.

Objective: To calculate the negative predictive value of AUS/FNAC in those patients with breast cancer who meet ACOSOG Z0011 criteria.

Conditions

Sponsors & Collaborators

  • Corporacion Parc Tauli

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2017-07-15
Completion
2017-07-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193008 on ClinicalTrials.gov